Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway

Cancer Research

Volumn 62, Issue 15, 2002, Pages 4316-4324

  Rapisarda, Annamaria ^a   Uranchimeg, Badarch ^a   Scudiero, Dominic A ^a   Selby, Mike ^a   Sausville, Edward A ^a   Shoemaker, Robert H ^a   Melillo, Giovanni ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CYCLOOXYGENASE 2; DNA TOPOISOMERASE INHIBITOR; GLYCOLYTIC ENZYME; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1 INHIBITOR; LUCIFERASE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; NSC 254681; NSC 359449; NSC 606985; NSC 639174; NSC 675865; QUINOCARMYCIN; QUINOCARMYCIN CITRATE; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANAEROBIC METABOLISM; ANGIOGENESIS; ARTICLE; CELL HYPOXIA; DIAGNOSTIC VALUE; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ENGINEERING; GLIOMA CELL; HUMAN; HUMAN CELL; MOLECULAR STABILITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA ANALYSIS; TRANSCRIPTION REGULATION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; GENE EXPRESSION; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; LYMPHOKINES; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); RESPONSE ELEMENTS; RNA, MESSENGER; TOPOTECAN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036682284     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target
2. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology
3. 2 tension
4. 2 sensing
5. 2-regulated prolyl hydroxylation
6. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
7. Loss of PTEN facilitates HIF-1-mediated gene expression
8. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
9. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
10. 2 homeostasis by hypoxia-inducible factor 1 α
11. HIF-1 α is required for solid tumor formation and embryonic vascularization
12. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
13. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
14. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth
15. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases
16. Levels of hypoxia-inducible factor-1α during breast carcinogenesis
17. Suppression of tumor growth through disruption of hypoxia-inducible transcription
18. Application of high-throughput, moleculartargeted screening to anticancer drug discovery
19. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter
20. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
21. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
22. A simple statistical parameter for use in evaluation and validation of high throughput screening assays
23. Topoisomerase poisons activate the transcription factor NF-κB in ACH-2 and CEM cells
24. Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture and in mice
25. Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine
26. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
27. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/ Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
28. Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents
29. Computer simulation of the binding of quinocarcin to DNA. Prediction of mode of action and absolute configuration
30. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes
31. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff
32. Synthesis and biological evaluation of quinocarcin derivatives: Thioalkyl-substituted quinones and hydroquinones
33. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
34. NF-κB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events
35. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model
36. Antiangiogenic potential of camptothecin and topotecan
37. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition
38. Cyclooxygenase: A target for colon cancer prevention
39. Transcriptional consequences of topoisomerase inhibition
40. Targeting to transcriptionally active loci by the hydrophilic N-terminal domain of Drosophila DNA topoisomerase I
41. Topoisomerase 1 enhances TFIID-TFIIA complex assembly during activation of transcription